Liver Cancer MDT staff

David contributes to Oxford as Professor of Cancer Medicine, where he has worked with colleagues to build a new Institute for Cancer Medicine and Cancer Hospital. He is an Honorary Professor of Oncology in Sichuan, Suchow, Xiamen, Shanghai and Seoul National Universities.

David has an international reputation for the treatment of and research into cancer and the quality of his work has been recognised by the award of several national and international prizes, including the Harvard Global Health Catalyst: Distinguished Leader Award, in recognition of his many years of leadership in global health work.

David was elected Fellow of the Academy of Medical Sciences (2000), the European Academy of Cancer Sciences (2004), Honorary Fellow of Royal College of General Practitioners (2007), Honorary Fellow of Association of Cancer Physicians (2018), appointed Commander of the British Empire (2002) and was elected President of the European Society of Medical Oncology in 2010.

He has served as health adviser to two British Prime Ministers and has supported National Cancer planning in the UK, Sub Saharan Africa (Ghana, Nigeria and Kenya), India, is a Trustee of the AMAR Foundation (an award winning charity which supports and rebuilds the lives of some of the poorest communities in the world, with a current focus on the Yazidi people) and works in partnership with Chinese colleagues to improve the delivery of cancer care in China.

He is Editor in Chief of The Oxford Textbooks of Oncology and Cancer Biology, was Editor in Chief of Annals of Oncology, established the Journal of Global Oncology and has initiated a course in Oxford on Global Health Diplomacy.

David has established a number of University biotech spin-outs, most recently Celleron Therapeutics, Oxford Cancer Biomarkers and SynOx.

Rebecca is a Consultant Clinical Oncologist and provides the radiation expertise for the liver MDT, including SABR, SIRT and palliative radiotherapy. She has led the national implementation of novel radiotherapy techniques such as Anal and Rectal IMRT which are now routinely delivered across the UK and the gold standard within prospective trials. As a member of the UK SABR Consortium she has recently published national guidelines on pelvic SABR reirradiation. Her research interests are personalised radiotherapy and reirradiation.

Fellow of the Royal College Radiologists, UK SABR Consortium Steering Committee Member, NCRI CTRad Committee Member, Gastro-Intestinal Cancer Audit Programme Board Member, NCRI Anorectal Clinical Studies Group Member.

Rebecca is a chief investigator, co-chief investigator, trial management group member, radiotherapy quality assurance reviewer or safety committee member for a number of Lower Gastrointestinal UK trials such as ART, PLATO, CEDAR, PRIME, HALT. She has over 50 peer reviewed articles published in international journals which can be reviewed at:

Dr Rebecca Muirhead - Google Scholar

Rachel has been Consultant Radiologist at the Churchill Hospital, Oxford and Honorary Senior Clinical Lecturer at the University of Oxford since 2002, following her first Consultant appointment in London in 1995. She trained in London and Vancouver and held a faculty position at New York University.

She is an examiner for the graduate entry medical students at the University of Oxford and the Royal College of Radiologists' representative for consultant appointments. Rachel is a tutor at Magdalen College Oxford and one of the College's admissions examiners.

Rachel's current interests and particular expertise are in the fields of magnetic resonance imaging, advanced imaging techniques and clinical trials in the assessment of treatment response to novel therapies for oncology patients.

Rachel's research has been highlighted in Nature-Clinical Practice and has received awards at the meetings of the prestigious Radiological Society of North America. She has contributed to more than 50 peer-reviewed publications and six book chapters.